KALV (KalVista Pharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by KALV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-11 | Bilal Arif | Chief Operations Officer | D | — | — |
| 2026-06-11 | Laurence Reid | Director | D | — | — |
| 2026-06-11 | Patrick Treanor | Director | D | — | — |
| 2026-06-11 | Paul K. Audhya | CHIEF MEDICAL OFFICER | D | — | — |
| 2026-06-11 | Brian Piekos | Chief Financial Officer | D | — | — |
| 2026-06-11 | Nicole Sweeny | Chief Commercial Officer | D | — | — |
| 2026-06-11 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | D | — | — |
| 2026-06-11 | Bethany Sensenig | Director | D | — | — |
| 2026-06-11 | William Fairey | Director | D | — | — |
| 2026-06-11 | Nancy Stuart | Director | D | — | — |
| 2026-06-11 | Brian JG Pereira | Director | D | — | — |
| 2026-06-11 | Edward W Unkart | Director | D | — | — |
| 2026-06-11 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | D | — | — |
| 2026-05-29 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | MIXED | — | — |
| 2026-05-27 | Paul K. Audhya | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-05-27 | Nicole Sweeny | Chief Commercial Officer | MIXED | — | — |
| 2026-05-27 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | MIXED | — | — |
| 2026-05-26 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-05-26 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | MIXED | — | — |
| 2026-05-26 | Paul K. Audhya | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-05-26 | Nicole Sweeny | Chief Commercial Officer | MIXED | — | — |
| 2026-05-26 | Brian Piekos | Chief Financial Officer | MIXED | — | — |
| 2026-05-19 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | MIXED | — | — |
| 2026-05-19 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-05-19 | Paul K. Audhya | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-05-13 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-04-20 | Paul K. Audhya | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-04-20 | Brian Piekos | Chief Financial Officer | MIXED | — | — |
| 2026-04-20 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-04-20 | Nicole Sweeny | Chief Commercial Officer | MIXED | — | — |
| 2026-03-27 | Venrock Healthcare Capital Partners EG, L.P. | 10%+ Owner | Sell | — | — |
| 2026-03-10 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-02-24 | Brian Piekos | Chief Financial Officer | MIXED | — | — |
| 2026-02-24 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-02-24 | Nicole Sweeny | Chief Commercial Officer | MIXED | — | — |
| 2026-02-24 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | MIXED | — | — |
| 2026-02-24 | Paul K. Audhya | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-02-19 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-02-19 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | MIXED | — | — |
| 2026-02-19 | Paul K. Audhya | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-02-13 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2026-01-21 | Paul K. Audhya | CHIEF MEDICAL OFFICER | A | — | — |
| 2026-01-21 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-01-21 | Brian Piekos | Chief Financial Officer | A | — | — |
| 2026-01-21 | Nicole Sweeny | Chief Commercial Officer | A | — | — |
| 2026-01-21 | Bilal Arif | Chief Operations Officer | A | — | — |
| 2025-12-09 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2025-12-04 | Nicole Sweeny | Chief Commercial Officer | MIXED | — | — |
| 2025-11-26 | Brian Piekos | Chief Financial Officer | MIXED | — | — |
| 2025-11-26 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,303,985 | — |
| — | 10%+ Owner | 5,278,985 | — |
| — | 10%+ Owner | 5,117,285 | — |
| — | 10%+ Owner | 5,089,354 | — |
| — | 10%+ Owner | 4,738,683 | — |
| — | Director | 2,508,279 | — |
| — | 10%+ Owner | 2,432,975 | — |
| — | 10%+ Owner | 2,191,576 | — |
| — | 10%+ Owner | 1,726,481 | — |
| — | 10%+ Owner | 1,698,554 | — |
| — | 10%+ Owner | 1,544,112 | — |
| — | Director | 1,441,070 | — |
| — | Director | 1,441,070 | — |
| — | Director | 1,144,179 | — |
| — | Director | 934,484 | — |
| — | Director | 591,070 | — |
| — | Director | 388,766 | — |
| — | CEO | 236,091 | — |
| — | CHIEF SCIENTIFIC OFFICER | 72,858 | — |
| — | 10%+ Owner | 50,562 | — |
| — | Senior Vice President, Medical | 40,886 | — |
| — | President & CEO | 36,640 | — |
| — | Director | 10,000 | — |
| — | Senior VP, Development | 7,500 | — |
| — | VP, Clinical Affairs | 4,664 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KALV quote page; the site-wide leaderboard is on the insider transactions hub.